JP2006526414A - 脱免疫化抗ｃｄ３抗体 - Google Patents

脱免疫化抗ｃｄ３抗体 Download PDF

Info

Publication number
JP2006526414A
JP2006526414A JP2006515055A JP2006515055A JP2006526414A JP 2006526414 A JP2006526414 A JP 2006526414A JP 2006515055 A JP2006515055 A JP 2006515055A JP 2006515055 A JP2006515055 A JP 2006515055A JP 2006526414 A JP2006526414 A JP 2006526414A
Authority
JP
Japan
Prior art keywords
antibody
deimmunized
chain variable
variable region
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006515055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526414A5 (enExample
Inventor
ラッセル ピー． ローター，
スーザン ファース−ナイト，
ダヤン ウー，
フランシス ジェイ． カール，
アニータ ハミルトン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2006526414A publication Critical patent/JP2006526414A/ja
Publication of JP2006526414A5 publication Critical patent/JP2006526414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006515055A 2003-06-02 2004-05-28 脱免疫化抗ｃｄ３抗体 Pending JP2006526414A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47515503P 2003-06-02 2003-06-02
PCT/US2004/017219 WO2004108158A1 (en) 2003-06-02 2004-05-28 De-immunized anti-cd3 antibody

Publications (2)

Publication Number Publication Date
JP2006526414A true JP2006526414A (ja) 2006-11-24
JP2006526414A5 JP2006526414A5 (enExample) 2007-07-12

Family

ID=33511652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515055A Pending JP2006526414A (ja) 2003-06-02 2004-05-28 脱免疫化抗ｃｄ３抗体

Country Status (7)

Country Link
US (1) US20070292416A1 (enExample)
EP (1) EP1658095A4 (enExample)
JP (1) JP2006526414A (enExample)
CN (1) CN1822857A (enExample)
AU (1) AU2004245038A1 (enExample)
CA (1) CA2527726A1 (enExample)
WO (1) WO2004108158A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502068A (ja) * 2014-12-08 2018-01-25 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
NZ599035A (en) 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
WO2010088522A2 (en) * 2009-01-30 2010-08-05 Ab Biosciences, Inc. Novel lowered affinity antibodies and uses therefor
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
ES2625470T3 (es) 2009-11-09 2017-07-19 Alexion Pharmaceuticals, Inc.. Reactivos y métodos para detectar glóbulos blancos asociados a HPN de tipo II y su identificación como factores de riesgo para trastornos trombóticos
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
EP2523976B1 (en) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
KR101800913B1 (ko) 2010-04-30 2017-12-20 알렉시온 파마슈티칼스, 인코포레이티드 항-c5a 항체들과 이 항체들을 이용하는 방법
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
MX341309B (es) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
JP6150734B2 (ja) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
CA2838246C (en) 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
EP3786183A3 (en) 2012-06-15 2021-06-09 Imaginab, Inc. Antigen binding constructs to cd3
JP6539585B2 (ja) 2013-02-01 2019-07-03 デンドロサイト バイオテック ピーティーワイ リミテッド 抗ｃｄ８３抗体及びその使用
EP2953971B1 (en) 2013-02-07 2023-03-01 CSL Limited Il-11r binding proteins and uses thereof
DK3074038T3 (en) 2013-11-28 2019-03-11 Csl Ltd METHOD OF TREATING DIABETIC NEPHROPATHY
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
ES2717308T3 (es) 2014-12-06 2019-06-20 Gemoab Monoclonals Gmbh Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
SG10201912051TA (en) 2015-11-27 2020-02-27 Csl Ltd Cd131 binding proteins and uses thereof
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP7733443B2 (ja) 2017-09-11 2025-09-03 モナシュ ユニバーシティー ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
CN111247165B (zh) 2017-10-18 2023-11-10 Csl有限公司 人血清白蛋白变体及其应用
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
PL3717011T3 (pl) 2017-11-29 2023-03-27 Csl Limited Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
PT3793586T (pt) 2018-05-16 2024-07-10 Csl Ltd Variantes do receptor solúvel do complemento de tipo 1 e sua utilização
MX2021000239A (es) 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
JP2023508023A (ja) 2019-12-20 2023-02-28 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP4182475A2 (en) 2020-07-17 2023-05-24 Onena Medicines S.L. Antibodies against lefty proteins
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
US12275798B2 (en) 2021-06-17 2025-04-15 Boehringer Ingelheim International Gmbh Tri-specific binding molecules
EP4581055A1 (en) 2022-08-31 2025-07-09 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09501824A (ja) * 1993-06-01 1997-02-25 アーチ ディベロプメント コーポレイション モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09501824A (ja) * 1993-06-01 1997-02-25 アーチ ディベロプメント コーポレイション モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502068A (ja) * 2014-12-08 2018-01-25 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
JP7095992B2 (ja) 2014-12-08 2022-07-05 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Also Published As

Publication number Publication date
CN1822857A (zh) 2006-08-23
CA2527726A1 (en) 2004-12-16
US20070292416A1 (en) 2007-12-20
EP1658095A4 (en) 2006-06-14
AU2004245038A1 (en) 2004-12-16
WO2004108158A1 (en) 2004-12-16
EP1658095A1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
JP2006526414A (ja) 脱免疫化抗ｃｄ３抗体
CN106977602B (zh) 一种抗pd1单克隆抗体、其药物组合物及其用途
JP4764627B2 (ja) 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体
KR100643818B1 (ko) 수상세포에 대한 인간 모노클로날 항체
US7556803B2 (en) Method for treating multiple myeloma
BG62656B1 (bg) Рекомбинантни антитела за хуманната медицина
US20200255536A1 (en) Target for b-cell disorders
WO2021052307A1 (zh) 一种抗b7-h3抗体及其应用
EP3498293A1 (en) Treatment of monogenic diseases with an anti-cd45rc antibody
KR20230166096A (ko) Cldn18.2 항원 결합 단백질 및 이의 적용
CN119060184B (zh) 抗rage抗体及其应用
CN119285778A (zh) 抗rage抗体及其应用
CN118146376B (zh) Hla-g抗体及其制备方法和用途
CN119371542B (zh) 抗rage抗体及其应用
CN118184783B (zh) Hla-g抗体及其制备方法和用途
RU2170256C2 (ru) Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
KR101176704B1 (ko) 원숭이 ｃｄ4에 특이적인 단일클론항체 및 이를 생산하는 융합세포주
WO2023134657A1 (zh) 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
CN118994392A (zh) 特异性结合cll1的抗体及其制法和应用
HK1059442B (en) Human monoclonal antibodies to dendritic cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100628

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110517